Christophe Bellanger
Université Paris-Saclay(FR)Assistance Publique – Hôpitaux de Paris(FR)Bicêtre Hospital(FR)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Cancer Immunotherapy and Biomarkers, Microscopic Colitis, Colorectal Cancer Treatments and Studies, Gallbladder and Bile Duct Disorders
Most-Cited Works
- → Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease(2020)99 cited
- → Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort(2021)52 cited
- → Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon(2021)14 cited
- → Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis: A Multicentre Cohort Study from the GETAID(2023)10 cited
- → Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors(2022)8 cited
- → Chronic gastrointestinal immune-related adverse events in patients exposed to immune checkpoint inhibitors(2024)6 cited